カテゴリー： QYResearch, 世界, 医療/バイオ

世界のウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場インサイト及び予測（スリンダック、イベルメクチン、その他）

◆英語タイトル：Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Insights, Forecast to 2028

QYResearchが発行した調査報告書（QY22JLX09308）◆商品コード：QY22JLX09308
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2022年7月（※2025年版があります。お問い合わせください。）
◆ページ数：94
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,900 ⇒換算￥744,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD7,350 ⇒換算￥1,117,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD9,800 ⇒換算￥1,489,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、ウィングレス＆統合（WNT）シグナル伝達経路阻害剤のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にウィングレス＆統合（WNT）シグナル伝達経路阻害剤の世界市場のxxx％を占める「スリンダック」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

ウィングレス＆統合（WNT）シグナル伝達経路阻害剤のグローバル主要企業には、Teva Pharmaceutical Industries、Sun Pharmaceutical Industries、Epic Pharma、Mylan N.V.、Bayer AG、Arbor Pharmaceuticals、Merck、Galderma、Edenbridge Pharmaceuticalsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

ウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場は、種類と用途によって区分されます。世界のウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
スリンダック、イベルメクチン、その他

【用途別セグメント】
病院、在宅医療、専門クリニック、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤製品概要
- 種類別市場（スリンダック、イベルメクチン、その他）
- 用途別市場（病院、在宅医療、専門クリニック、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界のウィングレス＆統合（WNT）シグナル伝達経路阻害剤販売量予測2017-2028
- 世界のウィングレス＆統合（WNT）シグナル伝達経路阻害剤売上予測2017-2028
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の地域別販売量
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別ウィングレス＆統合（WNT）シグナル伝達経路阻害剤販売量
- 主要メーカー別ウィングレス＆統合（WNT）シグナル伝達経路阻害剤売上
- 主要メーカー別ウィングレス＆統合（WNT）シグナル伝達経路阻害剤価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（スリンダック、イベルメクチン、その他）
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の種類別販売量
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の種類別売上
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の種類別価格
・用途別市場規模（病院、在宅医療、専門クリニック、その他）
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の用途別販売量
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の用途別売上
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の用途別価格
・北米市場
- 北米のウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場規模（種類別、用途別）
- 主要国別のウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパのウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場規模（種類別、用途別）
- 主要国別のウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋のウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場規模（種類別、用途別）
- 主要国別のウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米のウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場規模（種類別、用途別）
- 主要国別のウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカのウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場規模（種類別、用途別）
- 主要国別のウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場規模（トルコ、サウジアラビア）
・企業情報
Teva Pharmaceutical Industries、Sun Pharmaceutical Industries、Epic Pharma、Mylan N.V.、Bayer AG、Arbor Pharmaceuticals、Merck、Galderma、Edenbridge Pharmaceuticals
・産業チェーン及び販売チャネル分析
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の産業チェーン分析
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の原材料
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の生産プロセス
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の販売及びマーケティング
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の産業動向
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤のマーケットドライバー
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の課題
- ウィングレス＆統合（WNT）シグナル伝達経路阻害剤の阻害要因
・主な調査結果

Wingless/integrated (WNT) signaling pathway has a crucial role in the development of pluripotent cells. Wnt inhibitors refer to the type of inhibitors that belong to small protein families, including Dkk, Wise/SOST, IGFBP, Waif1, Tiki1, sFRP, WIF, Cerberus, Shisa, and APCDD1.The main purpose of these inhibitors is antagonizing Wnt signaling by preventing Wnt receptor maturation or ligand–receptor interactions.
Market Analysis and Insights: Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market
The global Wingless and Integrated (WNT) Signaling Pathway Inhibitors market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Sulindac accounting for % of the Wingless and Integrated (WNT) Signaling Pathway Inhibitors global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Wingless and Integrated (WNT) Signaling Pathway Inhibitors market size is valued at US$ million in 2021, while the North America and Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Wingless and Integrated (WNT) Signaling Pathway Inhibitors market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Wingless and Integrated (WNT) Signaling Pathway Inhibitors market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Wingless and Integrated (WNT) Signaling Pathway Inhibitors market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Wingless and Integrated (WNT) Signaling Pathway Inhibitors market.
Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Scope and Market Size
Wingless and Integrated (WNT) Signaling Pathway Inhibitors market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Wingless and Integrated (WNT) Signaling Pathway Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Sulindac
Ivermectin
Others
Segment by Application
Hospitals
Homecare
Specialty Clinics
Others
By Company
Teva Pharmaceutical Industries
Sun Pharmaceutical Industries
Epic Pharma
Mylan N.V.
Bayer AG
Arbor Pharmaceuticals
Merck
Galderma
Edenbridge Pharmaceuticals
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Sulindac
1.2.3 Ivermectin
1.2.4 Others
1.3 Market by Application
1.3.1 Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Homecare
1.3.4 Specialty Clinics
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Perspective (2017-2028)
2.2 Wingless and Integrated (WNT) Signaling Pathway Inhibitors Growth Trends by Region
2.2.1 Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Wingless and Integrated (WNT) Signaling Pathway Inhibitors Historic Market Size by Region (2017-2022)
2.2.3 Wingless and Integrated (WNT) Signaling Pathway Inhibitors Forecasted Market Size by Region (2023-2028)
2.3 Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Dynamics
2.3.1 Wingless and Integrated (WNT) Signaling Pathway Inhibitors Industry Trends
2.3.2 Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Drivers
2.3.3 Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Challenges
2.3.4 Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Wingless and Integrated (WNT) Signaling Pathway Inhibitors Players by Revenue
3.1.1 Global Top Wingless and Integrated (WNT) Signaling Pathway Inhibitors Players by Revenue (2017-2022)
3.1.2 Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Revenue Market Share by Players (2017-2022)
3.2 Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Wingless and Integrated (WNT) Signaling Pathway Inhibitors Revenue
3.4 Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Concentration Ratio
3.4.1 Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Wingless and Integrated (WNT) Signaling Pathway Inhibitors Revenue in 2021
3.5 Wingless and Integrated (WNT) Signaling Pathway Inhibitors Key Players Head office and Area Served
3.6 Key Players Wingless and Integrated (WNT) Signaling Pathway Inhibitors Product Solution and Service
3.7 Date of Enter into Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Wingless and Integrated (WNT) Signaling Pathway Inhibitors Breakdown Data by Type
4.1 Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Historic Market Size by Type (2017-2022)
4.2 Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Forecasted Market Size by Type (2023-2028)
5 Wingless and Integrated (WNT) Signaling Pathway Inhibitors Breakdown Data by Application
5.1 Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Historic Market Size by Application (2017-2022)
5.2 Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size (2017-2028)
6.2 North America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type
6.2.1 North America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type (2017-2022)
6.2.2 North America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type (2023-2028)
6.2.3 North America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Share by Type (2017-2028)
6.3 North America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application
6.3.1 North America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application (2017-2022)
6.3.2 North America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application (2023-2028)
6.3.3 North America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Share by Application (2017-2028)
6.4 North America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Country
6.4.1 North America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Country (2017-2022)
6.4.2 North America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size (2017-2028)
7.2 Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type
7.2.1 Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type (2017-2022)
7.2.2 Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type (2023-2028)
7.2.3 Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Share by Type (2017-2028)
7.3 Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application
7.3.1 Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application (2017-2022)
7.3.2 Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application (2023-2028)
7.3.3 Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Share by Application (2017-2028)
7.4 Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Country
7.4.1 Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Country (2017-2022)
7.4.2 Europe Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size (2017-2028)
8.2 Asia-Pacific Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type
8.2.1 Asia-Pacific Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Share by Type (2017-2028)
8.3 Asia-Pacific Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application
8.3.1 Asia-Pacific Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Share by Application (2017-2028)
8.4 Asia-Pacific Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Region
8.4.1 Asia-Pacific Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size (2017-2028)
9.2 Latin America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type
9.2.1 Latin America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type (2017-2022)
9.2.2 Latin America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type (2023-2028)
9.2.3 Latin America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Share by Type (2017-2028)
9.3 Latin America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application
9.3.1 Latin America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application (2017-2022)
9.3.2 Latin America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application (2023-2028)
9.3.3 Latin America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Share by Application (2017-2028)
9.4 Latin America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Country
9.4.1 Latin America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Country (2017-2022)
9.4.2 Latin America Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size (2017-2028)
10.2 Middle East & Africa Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type
10.2.1 Middle East & Africa Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Share by Type (2017-2028)
10.3 Middle East & Africa Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application
10.3.1 Middle East & Africa Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Share by Application (2017-2028)
10.4 Middle East & Africa Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Country
10.4.1 Middle East & Africa Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Teva Pharmaceutical Industries
11.1.1 Teva Pharmaceutical Industries Company Details
11.1.2 Teva Pharmaceutical Industries Business Overview
11.1.3 Teva Pharmaceutical Industries Wingless and Integrated (WNT) Signaling Pathway Inhibitors Introduction
11.1.4 Teva Pharmaceutical Industries Revenue in Wingless and Integrated (WNT) Signaling Pathway Inhibitors Business (2017-2022)
11.1.5 Teva Pharmaceutical Industries Recent Developments
11.2 Sun Pharmaceutical Industries
11.2.1 Sun Pharmaceutical Industries Company Details
11.2.2 Sun Pharmaceutical Industries Business Overview
11.2.3 Sun Pharmaceutical Industries Wingless and Integrated (WNT) Signaling Pathway Inhibitors Introduction
11.2.4 Sun Pharmaceutical Industries Revenue in Wingless and Integrated (WNT) Signaling Pathway Inhibitors Business (2017-2022)
11.2.5 Sun Pharmaceutical Industries Recent Developments
11.3 Epic Pharma
11.3.1 Epic Pharma Company Details
11.3.2 Epic Pharma Business Overview
11.3.3 Epic Pharma Wingless and Integrated (WNT) Signaling Pathway Inhibitors Introduction
11.3.4 Epic Pharma Revenue in Wingless and Integrated (WNT) Signaling Pathway Inhibitors Business (2017-2022)
11.3.5 Epic Pharma Recent Developments
11.4 Mylan N.V.
11.4.1 Mylan N.V. Company Details
11.4.2 Mylan N.V. Business Overview
11.4.3 Mylan N.V. Wingless and Integrated (WNT) Signaling Pathway Inhibitors Introduction
11.4.4 Mylan N.V. Revenue in Wingless and Integrated (WNT) Signaling Pathway Inhibitors Business (2017-2022)
11.4.5 Mylan N.V. Recent Developments
11.5 Bayer AG
11.5.1 Bayer AG Company Details
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Wingless and Integrated (WNT) Signaling Pathway Inhibitors Introduction
11.5.4 Bayer AG Revenue in Wingless and Integrated (WNT) Signaling Pathway Inhibitors Business (2017-2022)
11.5.5 Bayer AG Recent Developments
11.6 Arbor Pharmaceuticals
11.6.1 Arbor Pharmaceuticals Company Details
11.6.2 Arbor Pharmaceuticals Business Overview
11.6.3 Arbor Pharmaceuticals Wingless and Integrated (WNT) Signaling Pathway Inhibitors Introduction
11.6.4 Arbor Pharmaceuticals Revenue in Wingless and Integrated (WNT) Signaling Pathway Inhibitors Business (2017-2022)
11.6.5 Arbor Pharmaceuticals Recent Developments
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Wingless and Integrated (WNT) Signaling Pathway Inhibitors Introduction
11.7.4 Merck Revenue in Wingless and Integrated (WNT) Signaling Pathway Inhibitors Business (2017-2022)
11.7.5 Merck Recent Developments
11.8 Galderma
11.8.1 Galderma Company Details
11.8.2 Galderma Business Overview
11.8.3 Galderma Wingless and Integrated (WNT) Signaling Pathway Inhibitors Introduction
11.8.4 Galderma Revenue in Wingless and Integrated (WNT) Signaling Pathway Inhibitors Business (2017-2022)
11.8.5 Galderma Recent Developments
11.9 Edenbridge Pharmaceuticals
11.9.1 Edenbridge Pharmaceuticals Company Details
11.9.2 Edenbridge Pharmaceuticals Business Overview
11.9.3 Edenbridge Pharmaceuticals Wingless and Integrated (WNT) Signaling Pathway Inhibitors Introduction
11.9.4 Edenbridge Pharmaceuticals Revenue in Wingless and Integrated (WNT) Signaling Pathway Inhibitors Business (2017-2022)
11.9.5 Edenbridge Pharmaceuticals Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界のウィングレス＆統合（WNT）シグナル伝達経路阻害剤市場インサイト及び予測（スリンダック、イベルメクチン、その他）(Global Wingless and Integrated (WNT) Signaling Pathway Inhibitors Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • サイクリン依存性キナーゼ（CDK）阻害剤のグローバル市場2023年：経口、静脈注射、その他
  • 世界のシグナリングテスター市場インサイト及び予測（2セル、4セル、8セル、その他）
  • 世界のインテグラーゼ阻害剤市場インサイト及び予測（ラルテグラビル、ドルテグラビル、エルビテグラビル、ビクテグラビル）
  • 世界のTRK阻害剤市場インサイト及び予測（第一世代、第二世代）
  • 世界の細胞周期阻害剤市場インサイト及び予測（CDK4阻害剤、CDK9阻害剤、CDK6阻害剤、その他）